BlossomHill Therapeutics (BLSM) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rezolute is the larger company by market cap ($465.6 million vs $461.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | RZLT |
|---|---|---|
| Share price | $14.51 | $3.92 |
| Market cap | $461.20M | $465.58M |
| 1-day change | +0.69% | -6.67% |
| YTD return | — | +66.10% |
| 1-year return | — | -60.12% |
| 5-year return | — | -26.87% |
| EPS (TTM) | $-10.38 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-77.60M |
| 52-week high | $27.99 | $11.17 |
| 52-week low | $11.02 | $1.07 |
| Distance from 52-week high | -48.16% | -64.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +143.97% | +175.51% |
| Average volume | 193.15K | 1.66M |
| Shares outstanding | 31.78M | 118.77M |
| Employees | 69 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
BLSM vs RZLT FAQ
Which is bigger, BlossomHill Therapeutics or Rezolute?
Rezolute (RZLT) is larger, with a market capitalization of $465.58M compared with $461.20M for BlossomHill Therapeutics (BLSM).
Are BlossomHill Therapeutics and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.